nach oben

European Journal of Pediatrics

Erschienen in:

01.07.2011 | Original Paper

The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study

verfasst von: Michelle L. Butt, Amanda Symington, Marianne Janes, LouAnn Elliott, Susan Steele, Bosco A. Paes

Erschienen in: European Journal of Pediatrics | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections and hospitalizations in children aged <2 years. The aim of this retrospective, single-centre study was to examine the characteristics of patients admitted to a paediatric intensive care unit (PICU) with RSV infection following the implementation of a RSV prophylaxis programme. Electronic hospital medical records of all PICU admissions for RSV infection were searched from 2003 to 2009. Data on baseline demographics, underlying disease, criteria for hospitalization, respiratory diagnosis and management, complications and palivizumab prophylaxis were collected. A total of 181 patients were admitted with RSV infection, accounting for 5.7% of all admissions. Eighty-four percent were ≤2 years of age. Majority (70.2%) had no underlying medical illness, and 79.6% received antibiotics as part of their medical treatment. Comparison of children aged ≤2 years and those >2 years revealed that fewer of the younger cohort (20.4% versus 79.3%; p < 0.001) had an underlying medical condition. RSV infection occurred in 3.3% (n = 6) children who had received palivizumab prophylaxis, and there were two deaths. The results indicate that >88% of all PICU admissions would not qualify for RSV prophylaxis under our established guidelines and 66% of the children aged ≤2 years were >36 weeks gestation and are not currently targeted for prophylaxis. The number of high-risk infants admitted to PICU with RSV infection has likely plateaued, and further reductions in admission rates may only be realised with the use of universal, vaccine immunization programmes.

Abman SH, Ogle JW, Butler-Simon N et al (1988) Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113:826–830PubMedCrossRef

American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis (2006) Diagnosis and management of bronchiolitis. Pediatrics 118:1774–1793CrossRef

Arnold SR, Wang EE, Law BJ et al (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 18:866–869PubMedCrossRef

Banerji A, Bell A, Mills EL et al (2001) Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 164:1847–1850PubMed

Banerji A, Greenberg D, White LF et al (2009) Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: a case–control study. Pediatr Infect Dis J 28:697–701PubMedCrossRef

Berger TM, Aebi C, Duppenthaler A, Swiss Pediatric Surveillance Unit et al (2009) Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005). Infection 37:109–116PubMedCrossRef

Bloemers BL, van Furth AM, Weijerman ME et al (2007) Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis—a prospective birth-cohort study. Pediatrics 120:e1076–e1081PubMedCrossRef

Committee on Infectious Diseases, From the American Academy of Pediatrics (2009) Policy statements, modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124:1694–1701CrossRef

Crowcroft NS, Zambon M, Harrison TG et al (2008) Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families. Eur J Pediatr 167:395–399PubMedCrossRef

10.

Duttweiler L, Nadal D, Frey B (2004) Pulmonary and systemic bacterial co-infections in severe RSV bronchiolitis. Arch Dis Child 89:1155–1157PubMedCrossRef

11.

Feltes TF, Cabalka AK, Meissner HC, Cardiac Synagis Study Group et al (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532–540PubMedCrossRef

12.

Figueras-Aloy J, Carbonell Estrany X, Comité de Estándares de la Sociedad Española de Neonatología (2010) Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation). An Paediatr (Barc) 73:98.e1–4

13.

Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group (2004) Case–control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 23:815–820PubMedCrossRef

14.

Frogel M, Nerwen C, Cohen A, Palivizumab Outcomes Registry Group et al (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 28:511–517PubMedCrossRef

15.

Hall CB, Weinberg GA, Iwane MK et al (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588–598PubMedCrossRef

16.

Horn SD, Smout RJ (2003) Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 143:S133–S141PubMed

17.

Kristensen K, Stensballe LG, Bjerre J et al (2009) Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 94:785–789PubMedCrossRef

18.

Law BJ, Langley JM, Allen U et al (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 23:806–814PubMedCrossRef

19.

Law BJ, MacDonald N, Langley J et al (1998) Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent? Paediatr Child Health 3:402–404PubMed

20.

Leader S, Kohlase K (2003) Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 143:S127–S132PubMed

21.

Levin D, Tribuzio M, Green-Wrzesinki T, Ames B et al (2010) Empiric antibiotics are justified for infants with respiratory syncytial virus lower respiratory tract infection presenting with respiratory failure: a prospective study and evidence review. Pediatr Crit Care Med 11:390–395PubMed

22.

López Guinea A, Casado Flores J, Martín Sobrino MA et al (2007) Severe bronchiolitis. Epidemiology and clinical course of 284 patients. An Pediatr (Barc) 67:116–122

23.

McLaurin KK, Leader S (2005) Growing impact of RSV hospitalizations among infants in the US, 1997–2002. Abstract 936. Presented at: Pediatric Academic Societies Annual Meeting, May 14–17, Washington, USA

24.

Meert K, Heidemann S, Abella B et al (1990) Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 18:1357–1359PubMedCrossRef

25.

Mori M, Kawashima H, Nakamura H et al, Surveillance Committee for Severe RSV Infection (2010) Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother (in press)

26.

Nair H, Nokes DJ, Gessner BD et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545–1555PubMedCrossRef

27.

Oh PI, Lanctot KL, Yoon A, Composs Investigators et al (2002) Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 21:512–518PubMedCrossRef

28.

Paes B, Li A, Lanctot KL et al (2010) CARESS: the Canadian Registry of Synagis (2006–2009). Abstract 753409. Presented at: Pediatric Academic Societies Annual Meeting, May 1st–4th, Vancouver, Canada

29.

Paes B, Steele S, Janes M et al (2009) Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada. Curr Med Res Opin 25:1585–1591PubMedCrossRef

30.

Paes B, Cole M, Latchman A et al (2009) Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Curr Med Res Opin 25:2191–2196PubMedCrossRef

31.

Paes B, Mitchell I, Li A et al (2010) Respiratory syncytial virus prophylaxis in special populations. Abstract 754319. Presented at: Pediatric Academic Societies Annual Meeting, May 1st–4th, Vancouver, Canada

32.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, IRIS Study Group et al (2003) Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22:823–827PubMedCrossRef

33.

Prais D, Schonfeld T, Amir J, Israeli Respiratory Syncytial Virus Monitoring Group (2003) Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics 112:548–552PubMedCrossRef

34.

Purcell K, Fergie J (2004) Driscoll children’s hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J 23:418–423PubMedCrossRef

35.

Ralston S, Hill V (2009) Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr 155:728–733PubMedCrossRef

36.

Randolph AG, Reder L, Englund JA (2004) Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit. Pediatr Infect Dis J 23:990–994PubMedCrossRef

37.

Resch B, Gusenleitner W, Müller W (2002) The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 30:193–197PubMedCrossRef

38.

Resch B, Berger A, Bernert G et al (2008) Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung. Monatsschr Kinderheilkd 156:381–383CrossRef

39.

Resch B, Gusenleitner W, Müller WD et al (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 25:120–122PubMedCrossRef

40.

Resch B, Gusenleitner W, Mueller WD (2007) Risk of concurrent bacterial infection in preterm infants hospitalized due to respiratory syncytial virus infection. Acta Paediatr 96:495–498PubMedCrossRef

41.

Sampalis JS, Langley J, Carbonell-Estrany X et al (2008) Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Mak 28:471–480CrossRef

42.

Samson L (2009) The Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Paediatr Child Health 14:521–526PubMed

43.

Schanzer DL, Langley JM, Tam TW (2006) Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 25:795–800PubMedCrossRef

44.

Simões EA, Carbonell-Estrany X, Fullarton JR, European RSV Risk Factor Study Group et al (2008) A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res 9:78PubMedCrossRef

45.

Simoes EA (2003) Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 143:S118–S126PubMedCrossRef

46.

The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531–537CrossRef

47.

Thibeault R, Gilca R, Cote S, De Serres G et al (2007) Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus. J Clin Virol 39:169–174PubMedCrossRef

48.

Thorburn K (2009) Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 94:99–103PubMedCrossRef

49.

Thorburn K, Harigopal S, Reddy V et al (2006) High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax 61:611–615PubMedCrossRef

50.

Thorburn K, Van Saene H (2007) Pulmonary bacterial co-infection in children ventilated for severe respiratory syncytial virus bronchiolitis is common. Intensive Care Med 33:565PubMedCrossRef

51.

Wang EE, Law BJ, Stephens D (1995) Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 126:212–219PubMedCrossRef

52.

Welliver RC (2003) Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 143:S112–S117PubMedCrossRef

53.

Wilkesmann A, Ammann RA, Schildgen O, DSM RSV Ped Study Group et al (2007) Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 26:485–491PubMedCrossRef

Titel: The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study
verfasst von: Michelle L. Butt
Amanda Symington
Marianne Janes
LouAnn Elliott
Susan Steele
Bosco A. Paes
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Pediatrics / Ausgabe 7/2011
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-010-1376-3

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

Painful ulcers in a 5-year-old girl

Transition from pediatric to adult health care: expectations of adolescents with chronic disorders and their parents

Clinical practice guidelines: what they are, why we need them and how they should be developed through rigorous evaluation

Shock: an unusual presentation of Kawasaki disease

A case report of hyperthyroid-associated thymic hypertrophy in a child, presenting as an anterior mediastinal mass

Serum asymmetric dimethylarginine (ADMA), homocysteine, vitamin B12, folate levels, and lipid profiles in epileptic children treated with valproic acid

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie